# Hypercholesterolemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypercholesterolemia

> 6 upcoming FDA catalysts in hypercholesterolemia: Praluent (alirocumab, REGN) on Dec 2026 to Mar 2027 (topline data readout); Praluent (alirocumab, REGN) on December 2026 (primary completion); laroprovstat (AZN) on Oct 2027 to Jan 2028 (topline data readout); laroprovstat (AZN) on October 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2026 to Mar 2027 | [Praluent (alirocumab) topline data readout](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| December 2026 | [Praluent (alirocumab) primary completion](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| Oct 2027 to Jan 2028 | [Laroprovstat topline data readout](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolemia | scheduled | "NCT07930507 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07930507)) |
| October 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolemia | scheduled | "NCT07930507 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07930507)) |
| Oct 2028 to Jan 2029 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia | scheduled | "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06492291)) |
| October 2028 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia | scheduled | "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06492291)) |

## Drugs

- [Praluent (alirocumab)](https://sec-api.dev/pdufa/alirocumab) (REGN)
- [Laroprovstat](https://sec-api.dev/pdufa/laroprovstat) (AZN)
- [Lipfendra (enlicitide decanoate)](https://sec-api.dev/pdufa/enlicitide-decanoate) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypercholesterolemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypercholesterolemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypercholesterolemia

```bibtex
@misc{secapidev_indications_hypercholesterolemia_20261116,
  title        = {Hypercholesterolemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypercholesterolemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypercholesterolemia_20261116","title":"Hypercholesterolemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypercholesterolemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
